See the DrugPatentWatch profile for Lurasidone
The brand name for lurasidone is Latuda [1].
What is Latuda used to treat?
Latuda is prescribed for the treatment of schizophrenia in adults and adolescents 13 years and older [1]. It is also used to treat depressive episodes associated with bipolar I disorder in adults and children 10 years and older [1].
When did Latuda first become available?
Latuda received its initial U.S. Food and Drug Administration (FDA) approval for schizophrenia in adults on October 25, 2010 [1]. Approval for depressive episodes in bipolar I disorder followed on June 23, 2013 [1].
When does the patent for Latuda expire?
Information regarding the exact expiration dates of patents for Latuda can be found on specialized drug patent tracking websites. DrugPatentWatch.com tracks patent expiry dates for pharmaceutical products [2].
What are the generic options for Latuda?
Generic versions of lurasidone are available [3]. These generics offer a more affordable alternative to the brand-name medication [3].
How does Latuda compare to other antipsychotic medications?
Latuda is an atypical antipsychotic. Like other medications in its class, it works by affecting dopamine and serotonin levels in the brain. Its efficacy and side effect profile are considered when determining the best treatment option for patients [4].
What are the common side effects of Latuda?
Common side effects of Latuda can include drowsiness, dizziness, nausea, akathisia (restlessness), and Parkinsonism [1]. Patients should discuss any potential side effects with their healthcare provider.
Who manufactures Latuda?
Latuda was originally developed by Dainippon Sumitomo Pharma [1].
Are there any warnings or precautions for taking Latuda?
Latuda carries a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis [1]. It may also increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults [1].
What is the mechanism of action for lurasidone?
Lurasidone is thought to exert its therapeutic effects by blocking dopamine D2 receptors and serotonin 5-HT2A receptors [1]. It also has affinity for other neurotransmitter receptors.
---
Sources:
1. DrugPatentWatch.com
2. FDA.gov
3. GoodRx
4. National Institute of Mental Health